Recent PVLA News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 11:30:15 AM
- Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 12:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 12:00:11 PM
- Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/31/2026 11:30:00 AM
- Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting • GlobeNewswire Inc. • 03/27/2026 02:30:00 PM
- Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026 • GlobeNewswire Inc. • 03/24/2026 11:30:00 AM
- Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:05:15 PM
- Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin • GlobeNewswire Inc. • 03/16/2026 11:30:00 AM
- Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations • GlobeNewswire Inc. • 03/10/2026 11:30:00 AM
- Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares • GlobeNewswire Inc. • 03/02/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 10:31:11 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/26/2026 10:29:53 PM
- Palvella Therapeutics Announces Pricing of Upsized Public Offering • GlobeNewswire Inc. • 02/26/2026 12:57:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/24/2026 09:27:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2026 09:23:07 PM
- Palvella Therapeutics Announces Proposed Public Offering • GlobeNewswire Inc. • 02/24/2026 09:05:00 PM
- Palvella Therapeutics shares surge on positive Phase 3 trial results • IH Market News • 02/24/2026 03:20:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2026 12:55:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2026 11:30:26 AM
- Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations • GlobeNewswire Inc. • 02/24/2026 11:30:00 AM
- Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations • GlobeNewswire Inc. • 02/23/2026 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2026 09:05:17 PM
